Article | Published:

Inhaled bacteriophage-loaded polymeric microparticles ameliorate acute lung infections

Nature Biomedical Engineeringvolume 2pages841849 (2018) | Download Citation

Abstract

Lung infections associated with pneumonia, or cystic fibrosis caused by Pseudomonas aeruginosa or other bacteria, result in significant morbidity and mortality, in part owing to the development of multidrug resistance, also against last-resort antibiotics. Lytic bacteriophages (that is, viruses that specifically kill bacteria) can reduce lung-associated infections, yet their clinical use is hindered by difficulties in delivering active phages to the deep lung. Here, we show that phage-loaded polymeric microparticles deposit throughout the lung via dry powder inhalation and that they deliver active phages. Phage-loaded microparticles effectively reduced P. aeruginosa infections and the associated inflammation in wild-type and cystic fibrosis transmembrane-conductance-regulator knockout mice, and rescued the mice from pneumonia-associated death. These polymeric microparticles might constitute a clinically translatable therapy for eradicating hospital-acquired lung infections and infections associated with cystic fibrosis.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Niederman, M. S. Challenges in the management of community-acquired pneumonia: the role of quinolones and moxifloxacin. Clin. Infect. Dis. 41, S158–S166 (2005).

  2. 2.

    Klevens, R. M. et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 122, 160–166 (2007).

  3. 3.

    Patient Registry 2015 Annual Data Report (Cystic Fibrosis Foundation, 2015).

  4. 4.

    Cohen, T. S. & Prince, A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat. Med. 18, 509–519 (2012).

  5. 5.

    Ciofu, O., Tolker-Nielsen, T., Jensen, P. O., Wang, H. & Hoiby, N. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. Adv. Drug Deliv. Rev. 85, 7–23 (2015).

  6. 6.

    Magill, S. S. et al. Multistate point-prevalence survey of health care-associated infections. N. Engl. J. Med. 370, 1198–1208 (2014).

  7. 7.

    Weiner, L. M. et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect. Control Hosp. Epidemiol. 37, 1288–1301 (2016).

  8. 8.

    Johansen, H. K., Moskowitz, S. M., Ciofu, O., Pressler, T. & Hoiby, N. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J. Cyst. Fibros. 7, 391–397 (2008).

  9. 9.

    Gould, I. M. The epidemiology of antibiotic resistance. Int. J. Antimicrob. Agents 32, S2–S9 (2008).

  10. 10.

    Gomez, M. I. & Prince, A. Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. Curr. Opin. Pharmacol. 7, 244–251 (2007).

  11. 11.

    Ciofi Degli Atti, M. et al. An outbreak of extremely drug-resistant Pseudomonas aeruginosa in a tertiary care pediatric hospital in Italy. BMC Infect. Dis. 14, 494 (2014).

  12. 12.

    Sprenger, M. & Fukuda, K. Antimicrobial resistance. New mechanisms, new worries. Science 351, 1263–1264 (2016).

  13. 13.

    Donlan, R. M. Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol. 17, 66–72 (2009).

  14. 14.

    Servick, K. Drug development. Beleaguered phage therapy trial presses on. Science 352, 1506 (2016).

  15. 15.

    Geier, M. R., Trigg, M. E. & Merril, C. R. Fate of bacteriophage lambda in non-immune germ-free mice. Nature 246, 221–223 (1973).

  16. 16.

    Bruttin, A. & Brüssow, H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother. 49, 2874–2878 (2005).

  17. 17.

    Hughes, K. A., Sutherland, I. W., Clark, J. & Jones, M. V. Bacteriophage and associated polysaccharide depolymerases—novel tools for study of bacterial biofilms. J. Appl. Microbiol. 85, 583–590 (1998).

  18. 18.

    Biswas, B. et al. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. 70, 204–210 (2002).

  19. 19.

    Chanishvili, N., Chanishvili, T., Tediashvili, M. & Barrow, P. A. Phages and their application against drug-resistant bacteria. J. Chem. Technol. Biotechnol. 76, 689–699 (2001).

  20. 20.

    Wright, A., Hawkins, C. H., Änggård, E. E. & Harper, D. R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34, 349–357 (2009).

  21. 21.

    Cho, I. & Blaser, M. J. The human microbiome: at the interface of health and disease. Nat. Rev. Genet. 13, 260–270 (2012).

  22. 22.

    Dufour, N., Delattre, R., Ricard, J. D. & Debarbieux, L. The lysis of pathogenic Escherichia coli by bacteriophages releases less endotoxin than by β-lactams. Clin. Infect. Dis. 64, 1582–1588 (2017).

  23. 23.

    Lu, T. K. & Collins, J. J. Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl Acad. Sci. USA 104, 11197–11202 (2007).

  24. 24.

    Bikard, D. et al. Exploiting CRISPR–Cas nucleases to produce sequence-specific antimicrobials. Nat. Biotechnol. 32, 1146–1150 (2014).

  25. 25.

    Citorik, R. J., Mimee, M. & Lu, T. K. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat. Biotechnol. 32, 1141–1145 (2014).

  26. 26.

    Yosef, I., Manor, M., Kiro, R. & Qimron, U. Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc. Natl Acad. Sci. USA 112, 7267–7272 (2015).

  27. 27.

    Schooley, R. T. et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob. Agents Chemother. 61, e00954-17 (2017).

  28. 28.

    Jennes, S. et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury—a case report. Crit. Care 21, 129 (2017).

  29. 29.

    Pabary, R. et al. Antipseudomonal bacteriophage reduces infective burden and inflammatory response in murine lung. Antimicrob. Agents Chemother. 60, 744–751 (2016).

  30. 30.

    Debarbieux, L. et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J. Infect. Dis. 201, 1096–1104 (2010).

  31. 31.

    Morello, E. et al. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS ONE 6, e16963 (2011).

  32. 32.

    Golshahi, L., Seed, K. D., Dennis, J. J. & Finlay, W. H. Toward modern inhalational bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia complex. J. Aerosol Med. Pulm. Drug Deliv. 21, 351–360 (2008).

  33. 33.

    Hraiech, S., Bregeon, F. & Rolain, J. M. Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status. Drug Des. Devel. Ther. 9, 3653–3663 (2015).

  34. 34.

    Yang, M. et al. Therapeutic effect of the YH6 phage in a murine hemorrhagic pneumonia model. Res. Microbiol. 166, 633–643 (2015).

  35. 35.

    Sahota, J. S. et al. Bacteriophage delivery by nebulization and efficacy against phenotypically diverse Pseudomonas aeruginosa from cystic fibrosis patients. J. Aerosol Med. Pulm. Drug Deliv. 28, 353–360 (2015).

  36. 36.

    Saussereau, E. et al. Effectiveness of bacteriophages in the sputum of cystic fibrosis patients. Clin. Microbiol. Infect. 20, O983–O990 (2014).

  37. 37.

    Saussereau, E. & Debarbieux, L. Bacteriophages in the experimental treatment of Pseudomonas aeruginosa infections in mice. Adv. Virus Res. 83, 123–141 (2012).

  38. 38.

    Alemayehu, D. et al. Bacteriophages phiMR299-2 and phiNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 3, e00029–e00012 (2012).

  39. 39.

    Roach, D. R. et al. Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe 22, 38–47.e34 (2017).

  40. 40.

    Golshahi, L., Lynch, K. H., Dennis, J. J. & Finlay, W. H. In vitro lung delivery of bacteriophages KS4-M and PhiKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J. Appl. Microbiol. 110, 106–117 (2011).

  41. 41.

    Puapermpoonsiri, U., Spencer, J. & Van der Walle, C. F. A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres. Eur. J. Pharm. Biopharm. 72, 26–33 (2009).

  42. 42.

    Matinkhoo, S., Lynch, K. H., Dennis, J. J., Finlay, W. H. & Vehring, R. Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections. J. Pharm. Sci. 100, 5197–5205 (2011).

  43. 43.

    Vandenheuvel, D. et al. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections. Eur. J. Pharm. Biopharm. 84, 578–582 (2013).

  44. 44.

    Leung, S. S. Y. et al. Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders. Int. J. Pharm. 521, 141–149 (2017).

  45. 45.

    Meenach, S. A. et al. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. Int. J. Nanomed. 8, 275–293 (2013).

  46. 46.

    Edwards, D. A. et al. Large porous particles for pulmonary drug delivery. Science 276, 1868–1871 (1997).

  47. 47.

    Champion, J. A., Walker, A. & Mitragotri, S. Role of particle size in phagocytosis of polymeric microspheres. Pharm. Res. 25, 1815–1821 (2008).

  48. 48.

    Ungaro, F. et al. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. J. Control. Release 135, 25–34 (2009).

  49. 49.

    Ungaro, F. et al. Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung. Eur. J. Pharm. Sci. 41, 60–70 (2010).

  50. 50.

    Dhanda, D. S., Tyagi, P., Mirvish, S. S. & Kompella, U. B. Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. J. Control. Release 168, 239–250 (2013).

  51. 51.

    d’Angelo, I. et al. Large porous particles for sustained release of a decoy oligonucelotide and poly(ethylenimine): potential for combined therapy of chronic Pseudomonas aeruginosa lung infections. Biomacromolecules 17, 1561–1571 (2016).

  52. 52.

    De Stefano, D. et al. A decoy oligonucleotide to NF-κB delivered through inhalable particles prevents LPS-induced rat airway inflammation. Am. J. Respir. Cell Mol. Biol. 49, 288–295 (2013).

  53. 53.

    Yang, Y. et al. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 30, 1947–1953 (2009).

  54. 54.

    Diraviam Dinesh, S. Artificial sputum medium. Protoc. Exch. https://doi.org/10.1038/protex.2010.212 (2010).

  55. 55.

    Safdar, N., Crnich, C. J. & Maki, D. G. The pathogenesis of ventilator-associated pneumonia: its relevance to developing effective strategies for prevention. Respir. Care 50, 725–739 (2005).

  56. 56.

    Makadia, H. K. & Siegel, S. J. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 3, 1377–1397 (2011).

  57. 57.

    Zhou, L. et al. Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 266, 1705–1708 (1994).

  58. 58.

    Poschet, J. F. et al. Molecular basis for defective glycosylation and Pseudomonas pathogenesis in cystic fibrosis lung. Proc. Natl Acad. Sci. USA 98, 13972–13977 (2001).

  59. 59.

    Pier, G. B. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. Proc. Natl Acad. Sci. USA 97, 8822–8828 (2000).

  60. 60.

    Liu, P. V. The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis: II. Effects of lecithinase and protease. J. Infect. Dis. 116, 112–116 (1966).

  61. 61.

    Foweraker, J. E., Laughton, C. R., Brown, D. F. & Bilton, D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J. Antimicrob. Chemother. 55, 921–927 (2005).

  62. 62.

    Winstanley, C., O’Brien, S. & Brockhurst, M. A. Pseudomonas aeruginosa evolutionary adaptation and diversification in cystic fibrosis chronic lung infections. Trends Microbiol. 24, 327–337 (2016).

  63. 63.

    Waters, E. M. et al. Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax 72, 666–667 (2017).

  64. 64.

    Singh, N., Vats, A., Sharma, A., Arora, A. & Kumar, A. The development of lower respiratory tract microbiome in mice. Microbiome 5, 61 (2017).

  65. 65.

    Barfod, K. K. et al. The murine lung microbiome changes during lung inflammation and intranasal vancomycin treatment. Open Microbiol. J. 9, 167–179 (2015).

  66. 66.

    Lehman, S. M. & Donlan, R. M. Bacteriophage-mediated control of a two-species biofilm formed by microorganisms causing catheter-associated urinary tract infections in an in vitro urinary catheter model. Antimicrob. Agents Chemother. 59, 1127–1137 (2015).

  67. 67.

    Adriaenssens, E. M. et al. CIM(®) monolithic anion-exchange chromatography as a useful alternative to CsCl gradient purification of bacteriophage particles. Virology 434, 265–270 (2012).

  68. 68.

    Adams, M. H. Bacteriophages (Interscience, New York, 1959).

Download references

Acknowledgements

This work was funded by the National Institutes of Health (R01 AR062920 (to A.J.G.), F30 AR069472 (to C.T.J.) and S10 OD016264 (to A.J.G.) and a research partnership between Children’s Healthcare of Atlanta and the Georgia Institute of Technology. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Centers for Disease Control and Prevention. Use of trade names and commercial sources is for identification only and does not imply endorsement by the Public Health Service or the US Department of Health and Human Services. We thank R. Hunt for advice and discussions over the course of the project. We also thank DFE Pharma for providing inhalation grade lactose Respitose ML006. Clinical strains were obtained from the Clinical and Translational Research Core of the CF@LANTA RDP Center, funded by the Cystic Fibrosis Foundation (MCCART15R0). PA103 was a gift from J. Goldberg at Emory University.

Author information

Author notes

    • Rachit Agarwal

    Present address: Centre for BioSystems Science and Engineering, Indian Institute of Science, Bangalore, India

Affiliations

  1. Woodruff School of Mechanical Engineering , Georgia Institute of Technology, Atlanta, GA, USA

    • Rachit Agarwal
    •  & Andrés J. García
  2. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, USA

    • Rachit Agarwal
    • , Christopher T. Johnson
    •  & Andrés J. García
  3. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA

    • Christopher T. Johnson
  4. Department of Pediatrics , Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA, USA

    • Barry R. Imhoff
    •  & Nael A. McCarty
  5. Center for Cystic Fibrosis and Airways Disease Research, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA, USA

    • Barry R. Imhoff
    •  & Nael A. McCarty
  6. Biofilm Laboratory, Centers for Disease Control and Prevention, Atlanta, GA, USA

    • Rodney M. Donlan

Authors

  1. Search for Rachit Agarwal in:

  2. Search for Christopher T. Johnson in:

  3. Search for Barry R. Imhoff in:

  4. Search for Rodney M. Donlan in:

  5. Search for Nael A. McCarty in:

  6. Search for Andrés J. García in:

Contributions

R.A., C.T.J., R.M.D., N.A.M. and A.J.G conceived and designed the experiments. R.A., C.T.J. and B.R.I. performed all the experiments. R.M.D. provided phage samples and advice on their use. B.R.I. and N.A.M. handled the cystic fibrosis knockout mice breeding, testing and care. The manuscript was written by R.A., N.A.M. and A.J.G. All authors discussed the results and reviewed the manuscript.

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Andrés J. García.

Supplementary Information

  1. Supplementary Information

    Supplementary figures and tables.

  2. Reporting Summary

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/s41551-018-0263-5